Pharmacy Information 药物资讯, 2024, 8(3), 56-61
Published Online May 2024 in Hans. http://www.hanspub.org/journal/pi https://doi.org/10.12677/pi.2024.83007
Study on the Therapeutic Effect of New Drug Bavencio (Avelumab)
Tianqi Qiu, Shujie Su
School of Pharmacy, Liaoning University, Shenyang Liaoning
Received: Apr. 1, 2024; accepted: Apr. 15, 2024; published: Apr. 22, 2024
stthnd
Abstract
In 2017, the United States FDA approved a number of new drugs, including Bavencio, a major in-gredient in Avelum ab. Today we will mainly introduce the development and approval of these new drugs. Avelum abababa Bavencio is an intravenous programmed cell death ligand-1-blocking human antibody which is used in the treatment of various tumors. It has accelerated approval in the United States for the treatment of Merkel’s cell carcinoma in adults and 12-year-old. Treat-ment of urothelial epithelium in the EU with Avelumab Cancer biologics license applications are being reviewed by FDA as a priority for different cancer treatments. This article will describe the therapeutic effects of the drug on Merkel’s cell carcinoma and metastatic urothelial carcinoma, summarize the pharmacodynamics, pharmacokinetic and side effects of the drug and discuss the further development of new Avelumab drugs.
Keywords
Avelumab, MCC, Pd-L1, JAVELIN200
Bavencio (Avelumab)新药的治疗作用研究
邱天琦，苏书杰
辽宁大学药学院，辽宁 沈阳
收稿日期：2024年4月1日；录用日期：2024年4月15日；发布日期：2024年4月22日
摘 要
2017年，美国食品药品监督管理局(FDA)加速批准了新药Bavencio，主要成分Avelumab。该药对转移
文章引用: 邱天琦, 苏书杰. Bavencio (Avelumab)新药的治疗作用研究[J]. 药物资讯, 2024, 8(3): 56-61. DOI: 10.12677/pi.2024.83007
Bavencio(Avelumab)新药的治疗作用研究 - 论文
